New Alzheimer’s drug shows promise, but side effects are a concern
SCMP, 15 Dec 2022
Subscribe to our YouTube channel for free here:
https://sc.mp/subscribe-youtube
An experimental drug for treating Alzheimer’s disease has successfully slowed cognitive decline in a trial. The drug makers, Japan-based Eisai and US-based Biogen, said the drug may carry a risk of dangerous side effects for certain patients, including brain swelling and micro-haemorrhages. The companies are seeking approval in the US, Europe and Japan.
Support us:
https://subscribe.scmp.com
Follow us on:
Website: https://www.scmp.com
Facebook: https://facebook.com/scmp
Twitter: https://twitter.com/scmpnews
Instagram: https://instagram.com/scmpnews
Linkedin: https://www.linkedin.com/company/south-china-morning-post/